- Home
- OMER
OMER
Omeros Corporation
as 07-26-2024 4:00pm EST
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 226.0M | IPO Year: | 2009 |
| Target Price: | N/A | AVG Volume (30 days): | 337.7K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.92 - $5.68 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Omeros Corporation (OMER)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Demopulos Peter A MD | OMER | Director | Nov 15 '23 | Buy | $1.53 | 10,000 | $15,300.00 | 208,516 | SEC Form 4 |
Latest Omeros Corporation News
OMER Breaking Stock News: Dive into OMER Ticker-Specific Updates for Smart Investing
Newsfile
2 months ago
Edge Total Intelligence Inc. Updates Status of MCTO
GlobeNewswire
2 months ago
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
GlobeNewswire
2 months ago
LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
GlobeNewswire
2 months ago
Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
GlobeNewswire
2 months ago
The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Compare OMER vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMER Omeros Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.